The Donor Eligibility System is an automated, web-accessible platform that assists in the donor eligibility determination process.
This system is specifically designed to provide tissue organizations with the ability to fully automate the donor eligibility process in a way that is not only compliant with FDA 21 CFR 1271 but also speeds up eligibility determination, reduces cost and allows clinicians more time for delivery of patient care.
40% reduction in time spent managing donor eligibility data
60% average reduction in cost when compared to developing proprietary solutions
120+ successful FDA inspections
15 years of successful operations and client support
Donor eligibility determination has historically been one of the areas in the tissue industry to receive the most scrutiny by the FDA. There is a significant amount of data that can be difficult to collect and many changing variables go into the decision making process that ultimately determine the acceptance of a donor. Incorrect donor eligibility determinations can result in tremendous liability risk and loss of revenue.
Our system incorporates input and data from multiple sources to successfully manage:
Based on inputs at each step of the donor eligibility process, the DONOR ELIGIBILITY SYSTEM by EVERSANA utilizes validated logic to identify high-risk areas and non-compliance in the donor information and helps you make the correct eligibility determination. Based on this determination, a compliant summary of records is created by the system according to the requirements of 21 CFR 1271.55(b).
The DONOR ELIGIBILITY SYSTEM by EVERSANA addresses common challenges for any size clinic through the following:
Experience hands-on, boutique-level customer service from our team of experts specializing in tissue regulation and FDA software requirements.
Whether it’s short-term assistance or a long-term relationship, our consulting experts and outsourced services team members can help you with your compliance needs. As your trusted
regulatory partner, we not only advise, but also specialize in implementation and results. Download one of our brochures to take an in-depth look of our services and case studies.
How can we help manage clinic operations in a compliant way. Schedule a demo session with us to see our state-of-the-art software in action.
Request A Demo
PRICENTRIC BRIEF: Biosimilar competition in Europe has brought about discounts to AbbVie’s blockbuster immunosuppressant drug Humira upwards of 80% during tendering Overall, biosimilar uptake has increased in Europe because biologic “copycats” are cheaper, but full faith in these products is still required from physicians and patients In the US, Coherus struck preemptively with a 33% discount to its Neulasta biosimilar to ensure market uptake THE DETAILS Health authorities the world over seek serious discounts when biosimilar competition enters the market, in many cases mandating discounts and price ceilings to both the originator drug and biosimilars or engaging in tendering practices that allow originator drugs and biosimilars to bid at a […]
